Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ian M Anderson

Showing results (71-80 of 86) with videos related to

Pageof 9
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 20, 2010
The HTR1A and HTR1B receptor genes influence stress-related information processingKrisztina Mekli, Antony Payton, Fabio Miyajima, et al.
Biological Psychiatry|January 11, 2011
The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactionsGabriella Juhasz, Jason S Dunham, Shane McKie, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|September 26, 2012
Genetic variants in the catechol-o-methyltransferase gene are associated with impulsivity and executive function: relevance for major depressionDorottya Pap, Xenia Gonda, Eszter Molnar, et al.
Journal of Psychopharmacology (Oxford, England)|April 10, 2014
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for PsychopharmacologyDavid S Baldwin, Ian M Anderson, David J Nutt, et al.
The Lancet. Psychiatry|April 1, 2017
Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trialIan M Anderson, Andrew Blamire, Tim Branton, et al.
The Lancet. Psychiatry|January 5, 2016
Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trialR Hamish McAllister-Williams, Ian M Anderson, Andreas Finkelmeyer, et al.
BMJ (Clinical Research Ed.)|November 2, 2018
Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)David S Kessler, Stephanie J MacNeill, Deborah Tallon, et al.
BMC Psychiatry|October 23, 2015
Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study)Liam Trevithick, R Hamish McAllister-Williams, Andrew Blamire, et al.
Bjpsych Open|February 15, 2019
Associations between childhood maltreatment and inflammatory markersAlish B Palmos, Stuart Watson, Tom Hughes, et al.
BMC Psychiatry|August 7, 2013
Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study)R Hamish McAllister-Williams, Eleanor Smith, Ian M Anderson, et al.
Pageof 9

Showing results (71-80 of 86) with videos related to

Sort By:
Pageof 9
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|July 20, 2010
The HTR1A and HTR1B receptor genes influence stress-related information processingKrisztina Mekli, Antony Payton, Fabio Miyajima, et al.
Biological Psychiatry|January 11, 2011
The CREB1-BDNF-NTRK2 pathway in depression: multiple gene-cognition-environment interactionsGabriella Juhasz, Jason S Dunham, Shane McKie, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|September 26, 2012
Genetic variants in the catechol-o-methyltransferase gene are associated with impulsivity and executive function: relevance for major depressionDorottya Pap, Xenia Gonda, Eszter Molnar, et al.
Journal of Psychopharmacology (Oxford, England)|April 10, 2014
Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for PsychopharmacologyDavid S Baldwin, Ian M Anderson, David J Nutt, et al.
The Lancet. Psychiatry|April 1, 2017
Ketamine augmentation of electroconvulsive therapy to improve neuropsychological and clinical outcomes in depression (Ketamine-ECT): a multicentre, double-blind, randomised, parallel-group, superiority trialIan M Anderson, Andrew Blamire, Tim Branton, et al.
The Lancet. Psychiatry|January 5, 2016
Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trialR Hamish McAllister-Williams, Ian M Anderson, Andreas Finkelmeyer, et al.
BMJ (Clinical Research Ed.)|November 2, 2018
Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR)David S Kessler, Stephanie J MacNeill, Deborah Tallon, et al.
BMC Psychiatry|October 23, 2015
Study protocol for the randomised controlled trial: Ketamine augmentation of ECT to improve outcomes in depression (Ketamine-ECT study)Liam Trevithick, R Hamish McAllister-Williams, Andrew Blamire, et al.
Bjpsych Open|February 15, 2019
Associations between childhood maltreatment and inflammatory markersAlish B Palmos, Stuart Watson, Tom Hughes, et al.
BMC Psychiatry|August 7, 2013
Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study)R Hamish McAllister-Williams, Eleanor Smith, Ian M Anderson, et al.
Pageof 9